Targeting the CSF1/CSF1R axis either alone or in combination with checkpoint blockade, or adoptive T cell therapy has decreased tumor MDSCs and improved anti-tumor responses in multiple tumors (Mok et al., 2014; Sluijter et al., 2014). The gene discussed is CSF1; the disease is neoplasm.